Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03839771
Brief Title: A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

First Submitted : February 6, 2019
First Submitted that Met QC Criteria : February 12, 2019
First Posted : February 15, 2019

Last Update Submitted that Met QC Criteria : February 12, 2019
Last Update Posted : February 15, 2019